PMID- 37708188 OWN - NLM STAT- MEDLINE DCOM- 20230918 LR - 20230920 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 18 IP - 9 DP - 2023 TI - A systematic review of whole disease models for informing healthcare resource allocation decisions. PG - e0291366 LID - 10.1371/journal.pone.0291366 [doi] LID - e0291366 AB - BACKGROUND: Whole disease models (WDM) are large-scale, system-level models which can evaluate multiple decision questions across an entire care pathway. Whilst this type of model can offer several advantages as a platform for undertaking economic analyses, the availability and quality of existing WDMs is unknown. OBJECTIVES: This systematic review aimed to identify existing WDMs to explore which disease areas they cover, to critically assess the quality of these models and provide recommendations for future research. METHODS: An electronic search was performed on multiple databases (MEDLINE, EMBASE, the NHS Economic Evaluation Database and the Health Technology Assessment database) on 23rd July 2023. Two independent reviewers selected studies for inclusion. Study quality was assessed using the National Institute for Health and Care Excellence (NICE) appraisal checklist for economic evaluations. Model characteristics were descriptively summarised. RESULTS: Forty-four WDMs were identified, of which thirty-two were developed after 2010. The main disease areas covered by existing WDMs are heart disease, cancer, acquired immune deficiency syndrome and metabolic disease. The quality of included WDMs is generally low. Common limitations included failure to consider the harms and costs of adverse events (AEs) of interventions, lack of probabilistic sensitivity analysis (PSA) and poor reporting. CONCLUSIONS: There has been an increase in the number of WDMs since 2010. However, their quality is generally low which means they may require significant modification before they could be re-used, such as modelling AEs of interventions and incorporation of PSA. Sufficient details of the WDMs need to be reported to allow future reuse/adaptation. CI - Copyright: (c) 2023 Jin et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. FAU - Jin, Huajie AU - Jin H AUID- ORCID: 0000-0002-3872-3998 AD - King's Health Economics (KHE), Institute of Psychiatry, Psychology & Neuroscience at King's College London, London, United Kingdom. FAU - Tappenden, Paul AU - Tappenden P AD - Health Economics and Decision Science, School of Health and Related Research, University of Sheffield, Sheffield, United Kingdom. FAU - Ling, Xiaoxiao AU - Ling X AD - Department of Statistical Science, University College London, London, United Kingdom. FAU - Robinson, Stewart AU - Robinson S AD - Newcastle University Business School, Newcastle, United Kingdom. FAU - Byford, Sarah AU - Byford S AUID- ORCID: 0000-0001-7084-1495 AD - King's Health Economics (KHE), Institute of Psychiatry, Psychology & Neuroscience at King's College London, London, United Kingdom. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Systematic Review DEP - 20230914 PL - United States TA - PLoS One JT - PloS one JID - 101285081 SB - IM MH - Humans MH - *Acquired Immunodeficiency Syndrome MH - Checklist MH - Cost-Benefit Analysis MH - Critical Pathways MH - Resource Allocation PMC - PMC10501624 COIS- The authors have declared that no competing interests exist. EDAT- 2023/09/14 18:43 MHDA- 2023/09/18 12:42 PMCR- 2023/09/14 CRDT- 2023/09/14 13:44 PHST- 2022/08/08 00:00 [received] PHST- 2023/08/28 00:00 [accepted] PHST- 2023/09/18 12:42 [medline] PHST- 2023/09/14 18:43 [pubmed] PHST- 2023/09/14 13:44 [entrez] PHST- 2023/09/14 00:00 [pmc-release] AID - PONE-D-22-22167 [pii] AID - 10.1371/journal.pone.0291366 [doi] PST - epublish SO - PLoS One. 2023 Sep 14;18(9):e0291366. doi: 10.1371/journal.pone.0291366. eCollection 2023.